Compare Repligen Corporation Common Stock (RGEN) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Tripadvisor Inc Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B), while Tripadvisor Inc Common Stock trades at $8.92 (market cap $1.05B). The key difference: Repligen Corporation Common Stock is far larger — about 10.8× Tripadvisor Inc Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Tripadvisor Inc Common Stock for 58 Days on average.
| RGEN | TRIP | |
|---|---|---|
Market Cap | $11.31B | $1.05B |
Volume | 1,216,919 | 2,724,828 |
Sector | Health | Consumer Cyclical |
52-Week High | $194.57 | $16.72 |
52-Week Low | $102.87 | $8.04 |
Typical Hold Time | 0 Days | 58 Days |
Enterprise Value | $11.20B | $1.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TripAdvisor (TRIP) trades at $8.74, up 0.23% with neutral technical indicators. The stock faces fundamental challenges with a high P/E ratio of 218.5 despite recent earnings misses, though it maintains strong gross margins above 90%. Recent news highlights institutional buying interest from Bank of America and State Street, while the company navigates competitive pressures in the travel platform space.
The outlook remains cautious with analyst consensus at Hold (62.5%) and a $13.58 price target offering 55% upside. Key risks include persistent earnings volatility, AI competition eroding market share, and negative cash flow trends. The investment case hinges on execution improvements and potential stabilization in core business segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
